T Cell-Mediated Tumor Killing-Related Classification of the Immune Microenvironment and Prognosis Prediction of Lung

Peng Ding1, Lichao Liu1, Yawen Bin1

  • 1Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China.

Abstract

Insights

Researchers identified lung adenocarcinoma (LUAD) subtypes based on T cell-mediated tumor killing (TTK) genes. This classification reveals distinct tumor immune microenvironments and predicts immunotherapy response, guiding personalized treatment strategies.

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • Immune checkpoint inhibitors (ICI) show promise for lung adenocarcinoma (LUAD) but identifying responsive subgroups remains challenging.
  • T cell-mediated tumor killing (TTK) is a key mechanism for ICI efficacy.
  • Subtyping LUAD based on TTK sensitivity genes can predict immunotherapy outcomes.

Purpose of the Study:

  • To identify LUAD subtypes based on genes associated with T cell-mediated tumor killing (TTK) sensitivity.
  • To assess the predictive significance of these subtypes for LUAD immunotherapies.
  • To understand the relationship between TTK, tumor immune microenvironment (TIME), and treatment response.

Main Methods:

  • High-throughput screening identified 6 differentially expressed genes regulating TTK sensitivity (GSTTK) in LUAD.
  • Unsupervised clustering categorized LUAD patients into distinct subgroups based on GSTTK expression.
  • Analysis of tumor immune microenvironment (TIME), somatic mutations, and immunotherapy response across subgroups.
  • Development and validation of a prognostic scoring algorithm based on GSTTK.

Main Results:

  • Two distinct LUAD subgroups were identified, characterized by different TTK immune microenvironments.
  • Significant variations in immune cell infiltration, survival, somatic mutations, and immunotherapy response were observed between subgroups.
  • The developed scoring algorithm accurately predicted overall survival rates in LUAD patients.

Conclusions:

  • TTK plays a critical role in shaping the tumor immune microenvironment (TIME) in LUAD.
  • Understanding diverse TTK modes enhances comprehension of TIME characteristics and T cell activity in LUAD.
  • This study provides a foundation for developing more effective immunotherapeutic strategies for LUAD.

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
629
The Tumor Microenvironment02:17

The Tumor Microenvironment

Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.7K
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.1K